Nature Publication: Selleckchem
RSL3 Drives Breakthrough in Ferroptosis Research
Date: Aug 2024
We are thrilled to announce that Selleckchem’s ferroptosis inducer, RSL3 (Cat. No. S8155), has been featured in a groundbreaking study published in Nature.
In the paper titled "7-Dehydrocholesterol dictates ferroptosis sensitivity", researchers utilised Selleckchem's RSL3 to investigate the regulatory mechanisms of lipid peroxidation and cell death.
Key Findings:
The study reveals that 7-Dehydrocholesterol (7-DHC) acts as a potent suppressor of ferroptosis.
RSL3 (S8155) was successfully used to induce ferroptosis in various cell lines, demonstrating its high potency and reliability as a chemical probe.
The consistent biological activity of Selleckchem's RSL3 allowed the authors to precisely dissect the metabolic pathways governing cell survival.
This publication highlights the critical role of high-purity chemical tools in decoding complex biological processes.
The selection of Selleckchem RSL3 by top-tier researchers reaffirms our commitment to providing reagents that deliver reproducible results in the most demanding experimental settings.
Fig.
1|. The genes involved in distal cholesterol synthesis differentially regulate ferroptosis.
We are excited to announce that Selleckchem’s TGF-β receptor inhibitor, SB431542 (Cat. No. S1067), played a crucial role in a major study published in Cell.
In the paper titled "The extracellular matrix integrates mitochondrial homeostasis", researchers utilised Selleckchem’s SB431542 to dissect the signalling mechanisms linking the extracellular matrix (ECM) to mitochondrial dynamics.
Key Findings:
The study discovered an evolutionarily conserved pathway where ECM remodelling triggers a TGF-β response to induce mitochondrial fission and the
mitochondrial unfolded protein response (UPRmt).
SB431542 (S1067) was used to inhibit TGF-β signalling, successfully blocking the ECM-induced mitochondrial fission.
This experiment was pivotal in proving that TGF-β is the key mediator of this crosstalk.
The high specificity of Selleckchem’s SB431542 allowed the authors to rule out off-target effects and firmly establish the molecular mechanism governing this adaptive immune and metabolic response.
This publication in Cell uncovers a fundamental connection between structural tissue changes and cellular metabolism.
The selection of Selleckchem SB431542 for mechanistic validation in such a high-profile study underscores its status as the "Gold Standard" inhibitor for TGF-β pathway research.
Figure S3 Mitochondria-regulating genes identified by a CRISPR-KO screen, related to Figure 3
Science Publication: Selleckchem Risdiplam Featured in Groundbreaking SMA Base Editing Study
Date: April 2023
We are proud to
announce that Selleckchem’s Risdiplam (Cat. No. S6925) has been featured in a landmark study published in Science.
In the paper titled "Base editing rescue of spinal muscular atrophy in cells and in mice", researchers utilised Selleckchem’s Risdiplam as a key small molecule tool to investigate therapeutic strategies for Spinal Muscular Atrophy (SMA).
Key Findings:
The study explores the use of base editors to permanently restore SMN protein levels, offering a potential one-time treatment for
SMA.
Risdiplam (S6925), a validated SMN2 splicing modifier, served as a critical benchmark and combinatorial agent in the study, helping to demonstrate the synergistic effects of combined therapeutic approaches.
The consistent performance of Selleckchem’s Risdiplam allowed the authors to generate reliable comparative data against novel genome editing platforms.
This publication in Science highlights the evolving landscape of SMA treatment.
The selection of Selleckchem Risdiplam by leading scientists for such high-stakes research underscores the trust placed in our chemical probes as the industry standard for validating next-generation genetic therapies.
Fig.
4. AAV9-ABE mediated rescue of Δ7SMA mice.
Selleckchem Highly Commended as "Chemical Probes Company of the Year" in 2018 CiteAb Awards
Date: Feb 2018
Selleckchem has been recognised by CiteAb, the world's leading life science data provider, for its outstanding contribution to the chemical probes market.
This "Highly Commended" distinction reflects the growing number of scientific citations and the trust researchers place in our inhibitor libraries.
Selleckchem Virtual Learning Series
Expand your knowledge from the comfort of your lab.
Our webinars feature industry experts discussing the latest trends in signal transduction and screening technologies.
Targeting the Undruggable: Advances in PROTACs & Molecular Glues
Date: October 24, 2025 | 1:00 PM EST
Speaker: Dr. Sarah Chen, Senior Application Scientist
Summary: Explore new strategies for targeted protein degradation using our latest linker libraries.
Optimising In Vivo Formulations for Kinase Inhibitors
Date: November 12, 2025 | 2:00 PM EST
Speaker: Dr. James Wilson, Principal Scientist, In Vivo Pharmacology
Summary: A practical guide to solving solubility challenges in animal studies.
Learn how to select the right vehicles (corn oil, PEG300, etc.) to maximise compound exposure.
Bring Selleckchem to Your Institution
We regularly host on-campus vendor shows and technical seminars at universities and research institutes worldwide.
Why Host a Show?
Exclusive Discounts: Get special pricing for on-site orders.
Technical Consultation: 1-on-1 troubleshooting with our local account managers.
Free Resources: Pick up hard copies of our catalogues and signalling pathway maps.
